Although (1) KDIGO 2017 [11] established guidelines for regular PTH and calcium screening according to CKD stage, with 1–3 months and 3–6 months intervals, respectively, in G5D, and (2) almost all patients undergoing dialysis develop SHPT, the overall reported testing rate is suboptimal worldwide [8,50,51]. The gene discussed is PTH; the disease is chronic kidney disease.